Development of novel activin-targeted therapeutics

Molecular Therapy

Volumn 23, Issue 3, 2015, Pages 434-444

  Chen, Justin L ^a,b,f   Walton, Kelly L ^a   Al Musawi, Sara L ^a   Kelly, Emily K ^a   Qian, Hongwei ^b   La, Mylinh ^c   Lu, Louis ^c   Lovrecz, George ^c   Ziemann, Mark ^b   Lazarus, Ross ^b   El Osta, Assam ^b   Gregorevic, Paul ^b,d,e,f   Harrison, Craig A ^a,f  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c CSIRO   (Australia)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ACTIVIN A PRODOMAIN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; ACTIVIN B PRODOMAIN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 2A; ACTIVIN RECEPTOR 2B; ALANINE; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; GROWTH DIFFERENTIATION FACTOR 11; HISTIDINE; LYSINE; MYELOPID; MYOSTATIN; PARVOVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA; TYROSINE; UNCLASSIFIED DRUG; ACTIVIN; BONE MORPHOGENETIC PROTEIN; GDF11 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MSTN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SPECIFICITY; EMBRYO; GENE EXPRESSION; GONADOTROPIN SECRETING CELL; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TIBIALIS ANTERIOR MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DEPENDOPARVOVIRUS; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PLASMID; PROCEDURES; PROTEIN TERTIARY STRUCTURE; SKELETAL MUSCLE;

ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEINS; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC VECTORS; GROWTH DIFFERENTIATION FACTORS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOSTATIN; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84924028266     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.221     Document Type: Article

References (43)

1. Makanji, Y, Walton, KL, Chan, KL, Gregorevic, P, Robertson, DM and Harrison, CA (2011). Generation of a specific activin antagonist by modification of the activin A propeptide. Endocrinology 152: 3758-3768.
2. Harrison, CA, Chan, KL and Robertson, DM (2006). Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities. Endocrinology 147: 2744-2753.
3. Massagué, J, Seoane, J and Wotton, D (2005). Smad transcription factors. Genes Dev 19: 2783-2810.
4. Cadena, SM, Tomkinson, KN, Monnell, TE, Spaits, MS, Kumar, R, Underwood, KW et al. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 109: 635-642.
5. Chantry, AD, Heath, D, Mulivor, AW, Pearsall, S, Baud'huin, M, Coulton, L et al. (2010). Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 25: 2633-2646.
6. Lotinun, S, Pearsall, RS, Davies, MV, Marvell, TH, Monnell, TE, Ucran, J et al. (2010). A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46: 1082-1088.
7. Lotinun, S, Pearsall, RS, Horne, WC and Baron, R (2012). Activin receptor signaling: a potential therapeutic target for osteoporosis. Curr Mol Pharmacol 5: 195-204.
8. Pearsall, RS, Canalis, E, Cornwall-Brady, M, Underwood, KW, Haigis, B, Ucran, J et al. (2008). A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105: 7082-7087.
9. Suragani, RN, Cadena, SM, Cawley, SM, Sako, D, Mitchell, D, Li, R et al. (2014). Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20: 408-414.
10. Dussiot, M, Maciel, TT, Fricot, A, Chartier, C, Negre, O, Veiga, J et al. (2014). An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med 20: 398-407.
11. Pistilli, EE, Bogdanovich, S, Goncalves, MD, Ahima, RS, Lachey, J, Seehra, J et al. (2011). Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol 178: 1287-1297.
12. Zhou, X, Wang, JL, Lu, J, Song, Y, Kwak, KS, Jiao, Q et al. (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142: 531-543.
13. Lach-Trifilieff, E, Minetti, GC, Sheppard, K, Ibebunjo, C, Feige, JN, Hartmann, S et al. (2014). An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 34: 606-618.
14. Fournier, B, Murray, B, Gutzwiller, S, Marcaletti, S, Marcellin, D, Bergling, S et al. (2012). Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol 32: 2871-2879.
15. Gray, AM and Mason, AJ (1990). Requirement for activin A and transforming growth factor-beta 1 pro-regions in homodimer assembly. Science 247: 1328-1330.
16. Harrison, CA, Al-Musawi, SL and Walton, KL (2011). Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands. Growth Factors 29: 174-186.
17. Walton, KL, Makanji, Y, Chen, J, Wilce, MC, Chan, KL, Robertson, DM et al. (2010). Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem 285: 17029-17037.
18. Annes, JP, Munger, JS and Rifkin, DB (2003). Making sense of latent TGFbeta activation. J Cell Sci 116(Pt 2): 217-224.
19. Ge, G, Hopkins, DR, Ho, WB and Greenspan, DS (2005). GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol 25: 5846-5858.
20. Wolfman, NM, McPherron, AC, Pappano, WN, Davies, MV, Song, K, Tomkinson, KN et al. (2003). Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100: 15842-15846.
21. Shi, M, Zhu, J, Wang, R, Chen, X, Mi, L, Walz, T et al. (2011). Latent TGF-β structure and activation. Nature 474: 343-349.
22. Böttinger, EP, Factor, VM, Tsang, ML, Weatherbee, JA, Kopp, JB, Qian, SW et al. (1996). The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci USA 93: 5877-5882.
23. Matsakas, A, Foster, K, Otto, A, Macharia, R, Elashry, MI, Feist, S et al. (2009). Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 19: 489-499.
24. Qiao, C, Li, J, Jiang, J, Zhu, X, Wang, B, Li, J et al. (2008). Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19: 241-254.
25. Chen, JL, Walton, KL, Winbanks, CE, Murphy, KT, Thomson, RE, Makanji, Y et al. (2014). Elevated expression of activins promotes muscle wasting and cachexia. FASEB J 28: 1711-1723.
26. Lee, SJ, Lee, YS, Zimmers, TA, Soleimani, A, Matzuk, MM, Tsuchida, K et al. (2010). Regulation of muscle mass by follistatin and activins. Mol Endocrinol 24: 1998-2008.
27. Lee, SJ, Reed, LA, Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102: 18117-18122.
28. Li, Q, Kumar, R, Underwood, K, O'Connor, AE, Loveland, KL, Seehra, JS et al. (2007). Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol Hum Reprod 13: 675-683.
29. Jones, KL, Mansell, A, Patella, S, Scott, BJ, Hedger, MP, de Kretser, DM et al. (2007). Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 104: 16239-16244.
30. Munz, B, Smola, H, Engelhardt, F, Bleuel, K, Brauchle, M, Lein, I et al. (1999). Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. EMBO J 18: 5205-5215.
31. Vale, W, Rivier, C, Hsueh, A, Campen, C, Meunier, H, Bicsak, T et al. (1988). Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44: 1-34.
32. Xia, Y and Schneyer, AL (2009). The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202: 1-12.
33. David, L, Mallet, C, Mazerbourg, S, Feige, JJ and Bailly, S (2007). Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
34. Morris, C (2013). Balancing Efficacy versus safety: learnings from development of myostatin inhibitiors. DACC News 29: 8.
35. Al-Musawi, SL, Walton, KL, Heath, D, Simpson, CM and Harrison, CA (2013). Species differences in the expression and activity of bone morphogenetic protein 15. Endocrinology 154: 888-899.
36. Simpson, CM, Stanton, PG, Walton, KL, Chan, KL, Ritter, LJ, Gilchrist, RB et al. (2012). Activation of latent human GDF9 by a single residue change (Gly 391 Arg) in the mature domain. Endocrinology 153: 1301-1310.
37. Walton, KL, Makanji, Y, Wilce, MC, Chan, KL, Robertson, DM and Harrison, CA (2009). A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J Biol Chem 284: 9311-9320.
38. de Kretser, DM, Bensley, JG, Pettilä, V, Linko, R, Hedger, MP, Hayward, S et al. (2013). Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Crit Care 17: R263.
39. Lee, SJ (2007). Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2: e789.
40. Makanji, Y, Harrison, CA, Stanton, PG, Krishna, R and Robertson, DM (2007). Inhibin A and B in vitro bioactivities are modified by their degree of glycosylation and their affinities to betaglycan. Endocrinology 148: 2309-2316.
41. Blankinship, MJ, Gregorevic, P, Allen, JM, Harper, SQ, Harper, H, Halbert, CL et al. (2004). Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 10: 671-678.
42. Dobin, A, Davis, CA, Schlesinger, F, Drenkow, J, Zaleski, C, Jha, S et al. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21.
43. Winbanks, CE, Wang, B, Beyer, C, Koh, P, White, L, Kantharidis, P et al. (2011). TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 286: 13805-13814.